Dr. Daniel Sepúlveda-Crespo earned his Chemical Engineering degree (2005-10) and Master's in Industrial Processes Engineering (2011) at UCM. In 2016, he earned the International Ph.D. mention in Molecular Biosciences from the UAM with a Summa Cum Laude distinction. During his pre- and postdoctoral positions at HGUGM (2012-18), he focused on developing novel nanocompounds for topical vaginal microbicides, aiming to prevent HIV and other sexually transmitted infections, including HSV-2 and HCV. His research enhanced the understanding of virus/host interactions emphasizing his commitment to translating research into tangible societal benefits. In 2018, he secured a postdoctoral contract at ULe through the JCyL/FEDER, redirecting his focus to drug discovery for neglected tropical diseases caused by human-threatening parasites, including gastrointestinal helminths. In 2019, he received the ONCE Foundation scholarship award 'Opportunity for Talent', securing it for two consecutive years for a research stay at CNM-ISCIII. In 2021, he obtained a Sara Borrell contract to investigate the impact of HCV elimination in HIV/HCV coinfected patients, assessing neutralizing antibodies against HCV and biomarkers linked to severe liver disease and HCV clearance during anti-HCV therapy. Currently, he led a project with a Miguel Servet contract, shifting his focus to novel dendritic nanosystems for diagnosing emerging viruses like Dengue or West Nile.
Dr. Daniel Sepúlveda-Crespo earned his Chemical Engineering degree (2005-10) and Master's in Industrial Processes Engineering (2011) at UCM. In 2016, he earned the International Ph.D. mention in Molecular Biosciences from the UAM with a Summa Cum Laude distinction. During his pre- and postdoctoral positions at HGUGM (2012-18), he focused on developing novel nanocompounds for topical vaginal microbicides, aiming to prevent HIV and other sexually transmitted infections, including HSV-2 and HCV. His research enhanced the understanding of virus/host interactions emphasizing his commitment to translating research into tangible societal benefits. In 2018, he secured a postdoctoral contract at ULe through the JCyL/FEDER, redirecting his focus to drug discovery for neglected tropical diseases caused by human-threatening parasites, including gastrointestinal helminths. In 2019, he received the ONCE Foundation scholarship award 'Opportunity for Talent', securing it for two consecutive years for a research stay at CNM-ISCIII. In 2021, he obtained a Sara Borrell contract to investigate the impact of HCV elimination in HIV/HCV coinfected patients, assessing neutralizing antibodies against HCV and biomarkers linked to severe liver disease and HCV clearance during anti-HCV therapy. Currently, he led a project with a Miguel Servet contract, shifting his focus to novel dendritic nanosystems for diagnosing emerging viruses like Dengue or West Nile.